215 related articles for article (PubMed ID: 37403358)
1. Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs.
Stahl EC; Sabo JK; Kang MH; Allen R; Applegate E; Kim SE; Kwon Y; Seth A; Lemus N; Salinas-Rios V; Soczek KM; Trinidad M; Vo LT; Jeans C; Wozniak A; Morris T; Kimberlin A; Foti T; Savage DF; Doudna JA
Mol Ther; 2023 Aug; 31(8):2422-2438. PubMed ID: 37403358
[TBL] [Abstract][Full Text] [Related]
2. Engineering self-deliverable ribonucleoproteins for genome editing in the brain.
Chen K; Stahl EC; Kang MH; Xu B; Allen R; Trinidad M; Doudna JA
Nat Commun; 2024 Feb; 15(1):1727. PubMed ID: 38409124
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.
Bloomer H; Khirallah J; Li Y; Xu Q
Adv Drug Deliv Rev; 2022 Feb; 181():114087. PubMed ID: 34942274
[TBL] [Abstract][Full Text] [Related]
4. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing.
Wei T; Cheng Q; Min YL; Olson EN; Siegwart DJ
Nat Commun; 2020 Jun; 11(1):3232. PubMed ID: 32591530
[TBL] [Abstract][Full Text] [Related]
5. Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins.
Metzger JM; Wang Y; Neuman SS; Snow KJ; Murray SA; Lutz CM; Bondarenko V; Felton J; Gimse K; Xie R; Li D; Zhao Y; Flowers MT; Simmons HA; Roy S; Saha K; Levine JE; Emborg ME; Gong S
Biomaterials; 2023 Feb; 293():121959. PubMed ID: 36527789
[TBL] [Abstract][Full Text] [Related]
6. Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.
Li S; Song Z; Liu C; Chen XL; Han H
ACS Appl Mater Interfaces; 2019 Dec; 11(51):47762-47770. PubMed ID: 31773942
[TBL] [Abstract][Full Text] [Related]
7. Pursuit of chlorovirus genetic transformation and CRISPR/Cas9-mediated gene editing.
Noel EA; Weeks DP; Van Etten JL
PLoS One; 2021; 16(10):e0252696. PubMed ID: 34673785
[TBL] [Abstract][Full Text] [Related]
8. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
[TBL] [Abstract][Full Text] [Related]
9. Preparation of NanoMEDIC Extracellular Vesicles to Deliver CRISPR-Cas9 Ribonucleoproteins for Genomic Exon Skipping.
Watanabe K; Gee P; Hotta A
Methods Mol Biol; 2023; 2587():427-453. PubMed ID: 36401042
[TBL] [Abstract][Full Text] [Related]
10. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
Li L; Hu S; Chen X
Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
[TBL] [Abstract][Full Text] [Related]
11. Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins Results in High Levels of Gene Editing in Primary Hepatocytes.
Rathbone T; Ates I; Fernando L; Addlestone E; Lee CM; Richards VP; Cottle RN
CRISPR J; 2022 Jun; 5(3):397-409. PubMed ID: 35238624
[TBL] [Abstract][Full Text] [Related]
12. Cas9 Ribonucleoprotein Complex Delivery: Methods and Applications for Neuroinflammation.
Campbell LA; Richie CT; Maggirwar NS; Harvey BK
J Neuroimmune Pharmacol; 2019 Dec; 14(4):565-577. PubMed ID: 31172397
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering.
Hamilton JR; Tsuchida CA; Nguyen DN; Shy BR; McGarrigle ER; Sandoval Espinoza CR; Carr D; Blaeschke F; Marson A; Doudna JA
Cell Rep; 2021 Jun; 35(9):109207. PubMed ID: 34077734
[TBL] [Abstract][Full Text] [Related]
14. Cytosolic delivery of CRISPR/Cas9 ribonucleoproteins for genome editing using chitosan-coated red fluorescent protein.
Qiao J; Sun W; Lin S; Jin R; Ma L; Liu Y
Chem Commun (Camb); 2019 Apr; 55(32):4707-4710. PubMed ID: 30942216
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9; A robust technology for producing genetically engineered plants.
Farooq R; Hussain K; Nazir S; Javed MR; Masood N
Cell Mol Biol (Noisy-le-grand); 2018 Nov; 64(14):31-38. PubMed ID: 30511631
[TBL] [Abstract][Full Text] [Related]
16. Finely tuned ionizable lipid nanoparticles for CRISPR/Cas9 ribonucleoprotein delivery and gene editing.
Im SH; Jang M; Park JH; Chung HJ
J Nanobiotechnology; 2024 Apr; 22(1):175. PubMed ID: 38609947
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
18. Confinement in Dual-Chain-Locked DNA Origami Nanocages Programs Marker-Responsive Delivery of CRISPR/Cas9 Ribonucleoproteins.
Xu Z; Dong Y; Ma N; Zhu X; Zhang X; Yin H; Chen S; Zhu JJ; Tian Y; Min Q
J Am Chem Soc; 2023 Dec; 145(49):26557-26568. PubMed ID: 38039555
[TBL] [Abstract][Full Text] [Related]
19. A stable DNA-free screening system for CRISPR/RNPs-mediated gene editing in hot and sweet cultivars of Capsicum annuum.
Kim H; Choi J; Won KH
BMC Plant Biol; 2020 Oct; 20(1):449. PubMed ID: 33004008
[TBL] [Abstract][Full Text] [Related]
20. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing.
Yao X; Lyu P; Yoo K; Yadav MK; Singh R; Atala A; Lu B
J Extracell Vesicles; 2021 Mar; 10(5):e12076. PubMed ID: 33747370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
